Myriad Genetics (NASDAQ:MYGN) had its target price dropped by research analysts at Barclays from $14.00 to $10.00 in a report released on Thursday, BenzingaRatingsTable reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s price objective would suggest a potential downside of 31.69% from the company’s current price.

A number of other brokerages have also commented on MYGN. TheStreet lowered Myriad Genetics from a “c-” rating to a “d+” rating in a report on Friday, March 13th. ValuEngine raised Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 12th. Piper Sandler reduced their target price on Myriad Genetics from to in a report on Friday, February 7th. Zacks Investment Research lowered Myriad Genetics from a “hold” rating to a “sell” rating and set a $21.00 target price on the stock. in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. reduced their target price on Myriad Genetics from $17.00 to $14.00 and set an “underweight” rating on the stock in a report on Friday, March 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $23.46.

NASDAQ MYGN traded up $0.18 on Thursday, reaching $14.64. The stock had a trading volume of 439,948 shares, compared to its average volume of 1,300,670. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.25 and a quick ratio of 3.00. The firm has a fifty day moving average of $17.19 and a two-hundred day moving average of $25.08. Myriad Genetics has a 1-year low of $9.24 and a 1-year high of $48.40. The company has a market cap of $1.17 billion, a P/E ratio of -40.67, a price-to-earnings-growth ratio of 8.18 and a beta of 1.41.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.01. Myriad Genetics had a positive return on equity of 5.42% and a negative net margin of 3.22%. The firm had revenue of $195.10 million for the quarter, compared to analyst estimates of $209.61 million. During the same period in the prior year, the firm posted $0.38 EPS. The company’s revenue for the quarter was down 10.0% on a year-over-year basis. Research analysts predict that Myriad Genetics will post 0.13 EPS for the current fiscal year.

In other news, insider Nicole Lambert sold 4,354 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $19.73, for a total transaction of $85,904.42. Following the sale, the insider now directly owns 59,150 shares of the company’s stock, valued at approximately $1,167,029.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC boosted its position in Myriad Genetics by 104.3% in the 4th quarter. Advisory Services Network LLC now owns 1,083 shares of the company’s stock valued at $29,000 after buying an additional 553 shares during the period. Evoke Wealth LLC purchased a new position in Myriad Genetics in the 3rd quarter valued at approximately $44,000. First Bank & Trust boosted its position in Myriad Genetics by 583.7% in the 4th quarter. First Bank & Trust now owns 2,181 shares of the company’s stock valued at $59,000 after buying an additional 1,862 shares during the period. Point72 Hong Kong Ltd purchased a new position in Myriad Genetics in the 4th quarter valued at approximately $62,000. Finally, Exchange Traded Concepts LLC purchased a new position in Myriad Genetics in the 4th quarter valued at approximately $85,000.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

See Also: How Short Selling Works

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.